Effect of Quercetin in myocardial infarctio
Phase 3
- Conditions
- myocardial infarction.ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction
- Registration Number
- IRCT20190428043405N1
- Lead Sponsor
- Research Center for Prevention of Cardiovascular Disease, Iran university of medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 88
Inclusion Criteria
Having the consent and willingness to cooperate in the project
Age range 35 to 65 years
Pass at least 2 months from the time of the first heart attack
BMI< 30 Kg/m2
Exclusion Criteria
consumption of vitamin supplements, antioxidants or omega-3 in the last 3 months
consumption of nonsteroidal anti-inflammatory drugs in the last 3 months
Having a history of chronic inflammatory, kidney, liver and thyroid disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ICAM-1. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: The level of ICAM-1 in serum with ELISA method.
- Secondary Outcome Measures
Name Time Method VCAM-1. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: The level of VCAM-1 in serum with ELISA method.;Systolic blood pressure. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: sphygmomanometer (mmHg).;Diastolic blood pressure. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: sphygmomanometer (mmHg).